| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.033 | 0.8 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | AMG-706 | FIMM | pan-cancer | AAC | -0.036 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.036 | 0.9 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.9 |